Fernanda Costa Svedman

Publications
CV
Public outreach and news

Articles

Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2025;43(8):467.e21-467.e29
Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab.
Hjorthén G; Costa Svedman F; Holmsten K; Ullén A
Article: ESMO OPEN. 2025;10(8):105512
Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer
Holmsten K; De Laere B; Sjodahl G; Lindberg J; Svedman FC; Ostling P; Eriksson P; Liedberg F; Ullen A
Article: RADIATION ONCOLOGY. 2024;19(1):74
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience
Svedman FC; Holmsten K; Jawdat F; Hailom W; Alm D; Grozman V; Ullen A
Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: CLINICAL GENITOURINARY CANCER. 2023;21(6):e438-e448
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
Holmsten K; Eknert J; Ofverholm E; Papantoniou D; Jawdat F; Verbiene I; Laurell A; Janes E; Sandzen J; Wojtyna-Dziedzic E; Lagstam I; Soderkvist K; Svedman FC; Liedberg F; Bruzelius M; Fransson A-S; Kjellstrom S; Omland LH; Pappot H; Ullen A
Journal article: ANNALS OF ONCOLOGY. 2023;34:s1213-s1214
Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Jawdat F; Svedman FC; Holmsten K; Grozman V; Alm D; Hailom WS; Ullen A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(1):75-85
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Arance A; De La Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Marquez-Rodas I; Spreafico A; Atkinson V; Svedman FC; Mant A; Khattak MA; Mihalcioiu C; Jang S; Cowey CL; Smith AD; Hawk N; Chen K; Diede SJ; Krepler C; Long GV
Journal article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2022;16:100328
217P Characterization of immune cells in the tumor microenvironment of advanced bladder cancer
Flaberg E; Turkki R; Paavolainen L; Krantz D; Välimäki K; Schoonenberg A; Moussaud E; Holmsten K; Svedman FC; Kallioniemi O; Abrahamsson J; Liedberg F; Sjödahl G; Pellinen T; Ullén A; Östling P
Article: CANCERS. 2022;14(15):3587
Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hoiom V; Brage SE
Article: CANCERS. 2022;14(3):702
Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
Costa Svedman F; Jalsenius M; Hoeiom V; Grozman V; Bergqvist M; Soederdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: LAKARTIDNINGEN. 2021;118:21115
[Overview of immune-related side effects from immune checkpoint inhibitors. Part 1: Gastrointestinal, lung and kidney toxicity].
Villabona Lisa Villabona L; Costa Svedman F; Jovanovic B; Kaneteg B; Eberhardson M; Magin H; Ullenhag G; Blomqvist L; Helgadottir H
Article: CANCER RESEARCH. 2021;81(9):2545-2555
Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy
Karlsson MJ; Svedman FC; Tebani A; Kotol D; Hoiom V; Fagerberg L; Edfors F; Uhlen M; Brage SE; Maddalo G
Article: CELL DEATH & DISEASE. 2019;10(9):663
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Das I; Wilhelm M; Hoiom V; Marquez RF; Svedman FC; Hansson J; Tuominen R; Brage SE
Article: PLOS ONE. 2018;13(11):e0206942
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: CELL DEATH & DISEASE. 2017;8(8):e3029
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Azimi A; Tuominen R; Svedman FC; Caramuta S; Pernemalm M; Stolt MF; Kanter L; Kharaziha P; Lehtio J; Johansson CH; Holom V; Hansson J; Brage SE
Article: CLINICS. 2009;64(7):641-644
PROSTASIN, A POTENTIAL TUMOR MARKER IN OVARIAN CANCER- A PILOT STUDY
Costa FP; Batista Junior EL; Zelmanowicz A; Svedman C; Devenz G; Alves S; Martins da Silva AS; Garicochea B
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2009;43(2):98-103
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines
Ullen A; Schwarz S; Lennartsson L; Kalkner K-M; Sandstrom P; Costa F; Lennernas B; Linder S; Nilsson S

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2021

Articles

Employments

Degrees and Education

News from KI

Events from KI